Cite
HARVARD Citation
Samalin, E. et al. (n.d.). P-080Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of oncology. p. . [Online].